Literature DB >> 3190743

Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts.

J K Horton1, P J Houghton, J A Houghton.   

Abstract

Tumor responsiveness to vincristine (VCR) was determined in xenografts of human rhabdomyosarcoma (RMS), in sublines of RMS selected in vivo for VCR resistance, in a KB line (KB-ChR8-5) selected in vitro for colchicine resistance, and in a colon adenocarcinoma (GC3). Sensitivity to VCR was associated with prolonged retention of VCR by the tumors after a single i.p. injection, whereas in tumors with acquired or intrinsic VCR resistance the drug was eliminated more rapidly. The sensitive tumors with prolonged retention of drug also showed increased levels of mitotic accumulation for up to 72 hr following VCR administration. There were good correlations between VCR sensitivity, VCR retention and the proposed mechanism of VCR cytotoxicity-mitotic arrest. A model has been developed consistent with data obtained that can explain the responsiveness to VCR of a series of human tumor xenografts irrespective of their tissue of origin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190743     DOI: 10.1016/0006-2952(88)90085-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

Review 1.  Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

Authors:  Nazila Kamaly; Zeyu Xiao; Pedro M Valencia; Aleksandar F Radovic-Moreno; Omid C Farokhzad
Journal:  Chem Soc Rev       Date:  2012-03-05       Impact factor: 54.564

Review 2.  Mitosis is not a key target of microtubule agents in patient tumors.

Authors:  Edina Komlodi-Pasztor; Dan Sackett; Julia Wilkerson; Tito Fojo
Journal:  Nat Rev Clin Oncol       Date:  2011-02-01       Impact factor: 66.675

3.  Too early to say, "no targeting of mitosis!".

Authors:  Katsumi Kitagawa
Journal:  Nat Rev Clin Oncol       Date:  2011-05-17       Impact factor: 66.675

4.  Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative.

Authors:  A Pierré; V Pérez; S Léonce; J A Boutin; D Saint-Dizier; P Hautefaye; G Lavielle; G Atassi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins.

Authors:  Marianne S Poruchynsky; Edina Komlodi-Pasztor; Shana Trostel; Julia Wilkerson; Marie Regairaz; Yves Pommier; Xu Zhang; Tapan Kumar Maity; Robert Robey; Mauricio Burotto; Dan Sackett; Udayan Guha; Antonio Tito Fojo
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-20       Impact factor: 11.205

6.  A new lipid-based nano formulation of vinorelbine.

Authors:  Fatemeh Bahadori; Gülaçtı Topçu; Mehmet S Eroğlu; Hayat Onyüksel
Journal:  AAPS PharmSciTech       Date:  2014-05-29       Impact factor: 3.246

7.  Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia.

Authors:  L D Mayer; R Nayar; R L Thies; N L Boman; P R Cullis; M B Bally
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine.

Authors:  Charles O Noble; Zexiong Guo; Mark E Hayes; James D Marks; John W Park; Christopher C Benz; Dmitri B Kirpotin; Daryl C Drummond
Journal:  Cancer Chemother Pharmacol       Date:  2009-01-30       Impact factor: 3.333

9.  Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models.

Authors:  M S Webb; T O Harasym; D Masin; M B Bally; L D Mayer
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

10.  Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours.

Authors:  L D Mayer; D Masin; R Nayar; N L Boman; M B Bally
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.